Diamyd Phase II study in cancer pain posted on ClinicalTrials.gov
Diamyd Medical´s US Phase II clinical trial, evaluating the ability of
the candidate drug NP2 Enkephalin to reduce cancer pain, is posted on
the ClinicalTrials.gov website.
Diamyd's Phase II multi-center, randomized, double-blind, placebo
controlled clinical trial with the candidate drug NP2 Enkephalin is
recruiting approximately 32 subjects with severe cancer pain. The study
is designed to provide an evaluation of the safety and effect of NP2
Enkephalin with regards to pain relief, other pain medication usage and
quality of life. The trial has a four week double-blind main study
period and an open label study extension wherein all patients will be
offered up to two additional doses of active NP2 Enkephalin.
The trial finalization date has preliminary been set to one year from
start date on ClinicalTrials.gov. Diamyd will give a more detailed
prognosis for finalization as soon as this can be better estimated from
the ongoing recruitment.
NTDDS (Nerve Targeting Drug Delivery System) represents a new class of
pharmaceutical products that delivers gene-based drugs directly to nerve
cells, providing a direct effect in the cells targeted by the treatment.
The drug candidate NP2 Enkephalin has been engineered to deliver the
human Enkephalin gene, which naturally produces opioid peptides involved
in pain control, directly to the site of pain in the nervous system.
The ClinicalTrials.gov website is a registry of federally and privately
supported clinical trials conducted in the United States and around the
world. The site is developed by the U.S. National Institutes of Health
(NIH), through its National Library of Medicine (NLM), in collaboration
with the Food and Drug Administration (FDA). Read more at
http://clinicaltrials.gov.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Phone: +46 8 661 0026
For pictures and press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
andreas.ericsson@diamyd.com
Phone: +46 8 661 0026
